Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise

SANGAMO THERAPEUTICS, INC

Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.
Retention program approved for US/UK employees; CEO eligible for up to $429,820, CFO up to $193,584.
Retention payments conditioned on achieving capital-raising milestones by end of 2024 or change of control.
Executives must remain employed through payment date; program highlights company's cash needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.